Back to results
US 12,421,502 B2Granted
Enhanced adoptive cell therapy
AssigneeTilt Biotherapeutics Oy
InventorsAkseli Hemminki, Markus Vähä-Koskela, Siri Tähtinen, Vincenzo Cerullo
Life of this patent
Estimating the term…
Abstract
There is disclosed oncolytic adenoviral vectors alone or together with therapeutic compositions for therapeutic uses and therapeutic methods for cancer. In one aspect, there is also disclosed the separate administration of adoptive cell therapeutic composition and oncolytic adenoviral vectors. Furthermore, there is disclosed a pharmaceutical kit and a pharmaceutical composition, both utilizing oncolytic adenoviral vectors.
Claims1
A serotype 3 (Ad3) oncolytic adenoviral vector comprising:
- (a) an hTERT promoter for tumor specific expression of E1A,
- (b) a deletion in the E3 area consisting of E3 9 kDa, E3 10.2 kDa, E3 15.2 kDa and E3 15.3 kDa, and
- (c) a CMV or E2F promoter and a CD40L cytokine transgene in the place of the deleted area of E3, wherein said CMV or E2F promoter is for the expression of said transgene,
- wherein said adenoviral vector does not contain a further cytokine transgene, and wherein reading frame gp19k in the E3 area is functional and intact.
1 more element
Dependencies are inferred from the claim text.